 | |
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider |
|
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C10H14N2 |
| Molar mass | 162.236 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Rivanicline (TC-2403, RJR-2403, (E)-metanicotine) is a drug which acts as a partial agonist at neural nicotinic acetylcholine receptors. It is subtype-selective, binding primarily to the α4β2 subtype. It has nootropic effects and was originally developed as a potential treatment for Alzheimer's disease,[1][2][3] but a second action that was subsequently found was that it inhibits the production of Interleukin-8 and thus produces an antiinflammatory effect, and so it has also been developed as a potential treatment for ulcerative colitis.[4] Rivanicline also has stimulant and analgesic actions which are thought to be mediated through stimulation of noradrenaline release,[5] and so it could also have other applications. It has been identified as constituent of tobacco as well.[6][7]
{{cite journal}}: Cite journal requires |journal= (help)
|
| |
|---|---|
| AChE inhibitor medications |
|
| Other medications |
|
| Experimental BACE inhibitors |
|
|
| |||||
|---|---|---|---|---|---|
| nAChRsTooltip Nicotinic acetylcholine receptors |
| ||||
| Precursors (and prodrugs) |
| ||||
| |||||
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
